Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aoi, 2000, GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration, Acta Neurochir, 142, 805, 10.1007/s007010070096
Aoi, 2000, Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system, Neurol Res, 22, 832, 10.1080/01616412.2000.11740761
Apostol, 2003, A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila, Proc Natl Acad Sci USA, 100, 5950, 10.1073/pnas.2628045100
Arrasate, 2004, Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature, 431, 805, 10.1038/nature02998
Auluck, 2002, Pharmacological prevention of Parkinson disease in Drosophila, Nat Med, 8, 1185, 10.1038/nm1102-1185
Bacq, 1965, Importance for radioprotective effect in mammals of pharmacological and biochemical actions of cysteamine and related substances, Ann Ist Super Sanità, 1, 639
Bailey, 2005, Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms, J Neurochem, 92, 83, 10.1111/j.1471-4159.2004.02839.x
Bailey, 2006, The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase, Neurobiol Aging, 27, 871, 10.1016/j.neurobiolaging.2005.04.001
Baquet, 2005, Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta, J Neurosci, 25, 6251, 10.1523/JNEUROSCI.4601-04.2005
Beal, 2003, Bioenergetic approaches for neuroprotection in Parkinson's disease, Ann Neurol, 53, S39, 10.1002/ana.10479
Berruyer, 2004, Vanin-1−/− mice exhibit a glutathione-mediated tissue resistance to oxidative stress, Mol Cell Biol, 24, 7214, 10.1128/MCB.24.16.7214-7224.2004
Bharath, 2002, Glutathione, iron and Parkinson's disease, Biochem Pharmacol, 64, 1037, 10.1016/S0006-2952(02)01174-7
Bibel, 2000, Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system, Genes Dev, 14, 2919, 10.1101/gad.841400
Biziagos, 1987, Effect of antiviral substances on hepatitis A virus replication in vitro, J Med Virol, 22, 57, 10.1002/jmv.1890220108
Bjorkqvist, 2008, A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease, J Exp Med, 205, 1869, 10.1084/jem.20080178
Boka, 1994, Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease, Neurosci Lett, 172, 151, 10.1016/0304-3940(94)90684-X
Borrell-Pages, 2006, Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase, J Clin Invest, 116, 1410, 10.1172/JCI27607
Bousquet, 2010, Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases, J Neurochem, 114, 1651, 10.1111/j.1471-4159.2010.06874.x
Caccamo, 2010, Critical role of transglutaminase and other stress proteins during neurodegenerative processes, Amino Acids, 38, 653, 10.1007/s00726-009-0428-3
Calkins, 2010, Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription, Exp Neurol, 224, 307, 10.1016/j.expneurol.2010.04.008
Cardoso, 2009, Huntington disease and other choreas, Neurol Clin, 27, 719, 10.1016/j.ncl.2009.04.001
Chai, 1999, Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro, Hum Mol Genet, 8, 673, 10.1093/hmg/8.4.673
Chang, 2006, Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons, Neurobiol Dis, 22, 388, 10.1016/j.nbd.2005.12.007
Chang, 1997, The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice, Mol Chem Neuropathol, 30, 187, 10.1007/BF02815097
Checkoway, 1998, Genetic polymorphisms in Parkinson's disease, Neurotoxicology, 19, 635
Checkoway, 1999, Epidemiologic approaches to the study of Parkinson's disease etiology, Epidemiology, 10, 327, 10.1097/00001648-199905000-00023
Coloso, 2006, Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues, Adv Exp Med Biol, 583, 25, 10.1007/978-0-387-33504-9_3
Cooper, 1998, Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture, Hum Mol Genet, 7, 783, 10.1093/hmg/7.5.783
Dalrymple, 2007, Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates, J Proteome Res, 6, 2833, 10.1021/pr0700753
Danzer, 2010, Heat-shock protein 70 modulates toxic extracellular {alpha}-synuclein oligomers and rescues trans-synaptic toxicity, Faseb J
Dawbarn, 2003, Neurotrophins and neurodegeneration, Neuropathol Appl Neurobiol, 29, 211, 10.1046/j.1365-2990.2003.00487.x
Dedeoglu, 2002, Therapeutic effects of cystamine in a murine model of Huntington's disease, J Neurosci, 22, 8942, 10.1523/JNEUROSCI.22-20-08942.2002
Demarco, 1965, Degradation of cystaldimine, the product of oxidative deamination of cystamine, Biochim Biophys Acta, 100, 89, 10.1016/0304-4165(65)90430-7
Di Leandro, 2008, Cystamine restores GSTA3 levels in Vanin-1 null mice, Free Radic Biol Med, 44, 1088, 10.1016/j.freeradbiomed.2007.12.015
Dong, 2005, Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease, Mol Ther, 11, 80, 10.1016/j.ymthe.2004.09.007
Dubinsky, 2006, CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease, Mov Disord, 21, 530, 10.1002/mds.20756
Dubow, 2007, Autonomic dysfunction in Parkinson's disease, Dis Mon, 53, 265, 10.1016/j.disamonth.2007.02.004
Emerich, 1992, A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy, Neurosci Biobehav Rev, 16, 437, 10.1016/S0149-7634(05)80185-X
Fitzmaurice, 2003, Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease, Mov Disord, 18, 969, 10.1002/mds.10486
Fox, 2004, Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation, J Neurochem, 91, 413, 10.1111/j.1471-4159.2004.02726.x
Fumagalli, 2006, Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease, Pharmacogenomics J, 6, 95, 10.1038/sj.tpj.6500360
Galpern, 1996, Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration, Cell Transplant, 5, 225, 10.1016/0963-6897(95)02030-6
Gibrat, 2010, Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor, Prog Neuropsychopharmacol Biol Psychiatry, 34, 193, 10.1016/j.pnpbp.2009.11.005
Gorman, 2005, Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells, Biochem Biophys Res Commun, 327, 801, 10.1016/j.bbrc.2004.12.066
Griffin, 2002, Transglutaminases: nature's biological glues, Biochem J, 368, 377, 10.1042/bj20021234
Grinberg, 2010, Brainstem pathology and non-motor symptoms in PD, J Neurol Sci, 289, 81, 10.1016/j.jns.2009.08.021
Halliday, 2010, The progression of pathology in Parkinson's disease, Ann NY Acad Sci, 1184, 188, 10.1111/j.1749-6632.2009.05118.x
Hamzehei, 1980, Inhibition of influenza A virus replication by rifampicin and selenocystamine, J Med Virol, 6, 169, 10.1002/jmv.1890060210
Hazeki, 1999, Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract, Biochem Biophys Res Commun, 256, 361, 10.1006/bbrc.1999.0337
Henchcliffe, 2008, Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis, Nat Clin Pract Neurol, 4, 600, 10.1038/ncpneuro0924
Hirsch, 2003, The role of glial reaction and inflammation in Parkinson's disease, Ann NY Acad Sci, 991, 214, 10.1111/j.1749-6632.2003.tb07478.x
Hirsch, 2009, Neuroinflammation in Parkinson's disease: a target for neuroprotection?, Lancet Neurol, 8, 382, 10.1016/S1474-4422(09)70062-6
Hodges, 2006, Regional and cellular gene expression changes in human Huntington's disease brain, Hum Mol Genet, 15, 965, 10.1093/hmg/ddl013
Hsu, 2008, Beneficial effects of treatment with cystamine on brain in NZB/WF1 mice, Eur J Pharmacol, 591, 307, 10.1016/j.ejphar.2008.06.078
Huxtable, 1992, Physiological actions of taurine, Physiol Rev, 72, 101, 10.1152/physrev.1992.72.1.101
Jain, 1991, Glutathione deficiency leads to mitochondrial damage in brain, Proc Natl Acad Sci USA, 88, 1913, 10.1073/pnas.88.5.1913
Jeitner, 2005, Mechanism for the inhibition of transglutaminase 2 by cystamine, Biochem Pharmacol, 69, 961, 10.1016/j.bcp.2004.12.011
Junn, 2003, Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies, Proc Natl Acad Sci USA, 100, 2047, 10.1073/pnas.0438021100
Karpuj, 2002, Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine, Nat Med, 8, 143, 10.1038/nm0202-143
Kaufmann, 2004, Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies, Neurology, 63, 1093, 10.1212/01.WNL.0000138500.73671.DC
Kirik, 2001, Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease, Eur J Neurosci, 13, 1589, 10.1046/j.0953-816x.2001.01534.x
Klegeris, 2007, Therapeutic approaches to inflammation in neurodegenerative disease, Curr Opin Neurol, 20, 351, 10.1097/WCO.0b013e3280adc943
Klepac, 2007, Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study, J Neurol, 254, 1676, 10.1007/s00415-007-0611-y
Kleta, 2004, Pharmacological treatment of nephropathic cystinosis with cysteamine, Expert Opin Pharmacother, 5, 2255, 10.1517/14656566.5.11.2255
Klucken, 2004, Hsp70 reduces alpha-synuclein aggregation and toxicity, J Biol Chem, 279, 25497, 10.1074/jbc.M400255200
Knott, 2000, Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2, Mol Cell Neurosci, 16, 724, 10.1006/mcne.2000.0914
Kollmann, 1970, Further studies on protection of DNA against ionizing radiation, Int J Radiat Biol Relat Stud Phys Chem Med, 18, 587, 10.1080/09553007014551521
Koo, 2002, Inhibitory effect of apoptosis in human astrocytes CCF-STTG1 cells by lemon oil, Pharmacol Res, 45, 469, 10.1006/phrs.2002.0986
Kordower, 2003, In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease, Ann Neurol, 53, S120, 10.1002/ana.10485
Kordower, 2000, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease, Science, 290, 767, 10.1126/science.290.5492.767
Krogh, 2008, Clinical aspects of bowel symptoms in Parkinson's disease, Acta Neurol Scand, 117, 60
Kuemmerle, 1999, Huntington aggregates may not predict neuronal death in Huntington's disease, Ann Neurol, 46, 842, 10.1002/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O
Lang, 2010, Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future, Nat Med, 16, 1223, 10.1038/nm.2220
Lee, 2004, Regulation of cysteine dioxygenase and gamma-glutamylcysteine synthetase is associated with hepatic cysteine level, J Nutr Biochem, 15, 112, 10.1016/j.jnutbio.2003.10.005
Lesort, 1999, Tissue transglutaminase is increased in Huntington's disease brain, J Neurochem, 73, 2018, 10.1046/j.1471-4159.1999.02018.x
Lesort, 2003, Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders, J Biol Chem, 278, 3825, 10.1074/jbc.M205812200
Levivier, 1995, Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease, J Neurosci, 15, 7810, 10.1523/JNEUROSCI.15-12-07810.1995
Lewis, 2005, Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach, J Neurol Neurosurg Psychiatry, 76, 343, 10.1136/jnnp.2003.033530
Maguire-Zeiss, 2008, alpha-Synuclein: a therapeutic target for Parkinson's disease?, Pharmacol Res, 58, 271, 10.1016/j.phrs.2008.09.006
Mandel, 2003, Neuroprotective strategies in Parkinson's disease: an update on progress, CNS Drugs, 17, 729, 10.2165/00023210-200317100-00004
Mastroberardino, 2002, Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease, Cell Death Differ, 9, 873, 10.1038/sj.cdd.4401093
McGeer, 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38, 1285, 10.1212/WNL.38.8.1285
McGeer, 2001, Inflammation in Parkinson's disease, Adv Neurol, 86, 83
Meade, 2002, Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice, J Comp Neurol, 449, 241, 10.1002/cne.10295
Mitra, 2009, Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease, J Biol Chem, 284, 4398, 10.1074/jbc.M806269200
Mitsui, 2002, Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins, J Neurosci, 22, 9267, 10.1523/JNEUROSCI.22-21-09267.2002
Mogi, 1994, Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients, Neurosci Lett, 165, 208, 10.1016/0304-3940(94)90746-3
Muchowski, 2005, Modulation of neurodegeneration by molecular chaperones, Nat Rev Neurosci, 6, 11, 10.1038/nrn1587
Muramatsu, 1978, A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues, Jpn J Pharmacol, 28, 259, 10.1254/jjp.28.259
Murer, 2001, Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease, Prog Neurobiol, 63, 71, 10.1016/S0301-0082(00)00014-9
Newton, 1997, Effect of polyamine-induced compaction and aggregation of DNA on the formation of radiation-induced strand breaks: quantitative models for cellular radiation damage, Radiat Res, 148, 272, 10.2307/3579612
Nucifora, 2001, Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity, Science, 291, 2423, 10.1126/science.1056784
O'Keeffe, 2009, Biomarkers in Huntington's and Parkinson's Disease, Ann NY Acad Sci, 1180, 97, 10.1111/j.1749-6632.2009.04943.x
Ogawa, 2002, Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease, Sci Aging Knowl Environ, 2002, pe16, 10.1126/sageke.2002.41.pe16
Olanow, 2008, Why have we failed to achieve neuroprotection in Parkinson's disease?, Ann Neurol, 64, S101
Park, 2010, Transglutaminase 2: a multi-functional protein in multiple subcellular compartments, Amino Acids, 39, 619, 10.1007/s00726-010-0500-z
Pasantes-Morales, 1981, The role of taurine in nervous tissue: its effects on ionic fluxes, Adv Exp Med Biol, 139, 273, 10.1007/978-1-4757-0402-0_18
Pavese, 2006, Microglial activation correlates with severity in Huntington disease: a clinical and PET study, Neurology, 66, 1638, 10.1212/01.wnl.0000222734.56412.17
Pearce, 1997, Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease, J Neural Transm, 104, 661, 10.1007/BF01291884
Perez, 1998, Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation, J Cell Biol, 143, 1457, 10.1083/jcb.143.6.1457
Perry, 1986, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients, Neurosci Lett, 67, 269, 10.1016/0304-3940(86)90320-4
Peterson, 1992, Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity, Can J Physiol Pharmacol, 70, 20, 10.1139/y92-004
Pillai, 2008, Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex, J Neurochem, 107, 941, 10.1111/j.1471-4159.2008.05665.x
Pinto, 2009, Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism, J Chromatogr B Analyt Technol Biomed Life Sci, 877, 3434, 10.1016/j.jchromb.2009.05.041
Pinto, 2005, Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease, J Neurochem, 94, 1087, 10.1111/j.1471-4159.2005.03255.x
Pitari, 1992, Enzymatic synthesis of S-aminoethyl-L-cysteine from pantetheine, Biochim Biophys Acta, 1116, 27, 10.1016/0304-4165(92)90124-D
Poewe, 2007, Dysautonomia and cognitive dysfunction in Parkinson's disease, Mov Disord, 22, S374, 10.1002/mds.21681
Porritt, 2005, Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons, Exp Neurol, 192, 226, 10.1016/j.expneurol.2004.11.030
Prescott, 1976, Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning, Lancet, 2, 109, 10.1016/S0140-6736(76)92842-7
Ratan, 1994, Oxidative stress induces apoptosis in embryonic cortical neurons, J Neurochem, 62, 376, 10.1046/j.1471-4159.1994.62010376.x
Riederer, 2000, Is there neuroprotection in Parkinson syndrome?, J Neurol, 247, IV/8
Saijo, 2009, A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death, Cell, 137, 47, 10.1016/j.cell.2009.01.038
Salam, 2002, Modulation of inflammatory paw oedema by cysteamine in the rat, Pharmacol Res, 45, 275, 10.1006/phrs.2002.0955
Sapp, 2001, Early and progressive accumulation of reactive microglia in the Huntington disease brain, J Neuropathol Exp Neurol, 60, 161, 10.1093/jnen/60.2.161
Saudou, 1998, Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell, 95, 55, 10.1016/S0092-8674(00)81782-1
Sechi, 1996, Reduced intravenous glutathione in the treatment of early Parkinson's disease, Prog Neuropsychopharmacol Biol Psychiatry, 20, 1159, 10.1016/S0278-5846(96)00103-0
Seroogy, 1994, Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs, J Comp Neurol, 342, 321, 10.1002/cne.903420302
Sharma, 1995, The uptake and metabolism of cystamine and taurine by isolated perfused rat and rabbit lungs, Int J Biochem Cell Biol, 27, 655, 10.1016/1357-2725(95)00038-Q
Shieh, 2008, Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice, Prog Neuropsychopharmacol Biol Psychiatry, 32, 1590, 10.1016/j.pnpbp.2008.06.003
Shin, 2005, Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity, J Cell Biol, 171, 1001, 10.1083/jcb.200508072
Shin, 2005, The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways, J Biol Chem, 280, 23727, 10.1074/jbc.M503326200
Shults, 1986, Huntington's disease: effect of cysteamine, a somatostatin-depleting agent, Neurology, 36, 1099, 10.1212/WNL.36.8.1099
Sian, 1994, Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia, Ann Neurol, 36, 348, 10.1002/ana.410360305
Singhrao, 1999, Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease, Exp Neurol, 159, 362, 10.1006/exnr.1999.7170
Smoluk, 1986, Equilibrium dialysis studies of the binding of radioprotector compounds to DNA, Radiat Res, 107, 194, 10.2307/3576807
Sofic, 1992, Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease, Neurosci Lett, 142, 128, 10.1016/0304-3940(92)90355-B
Stack, 2008, Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease, Biochim Biophys Acta, 1782, 151, 10.1016/j.bbadis.2007.12.006
Steffan, 2000, The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription, Proc Natl Acad Sci USA, 97, 6763, 10.1073/pnas.100110097
Stuart, 1966, The radioprotection of Saccharomyces cerevisiae by cystamine as measured by different criteria of cell damage, Radiat Res, 28, 609, 10.2307/3571989
Su, 2009, Mutant alpha-synuclein overexpression mediates early proinflammatory activity, Neurotox Res, 16, 238, 10.1007/s12640-009-9053-x
Su, 2008, Synuclein activates microglia in a model of Parkinson's disease, Neurobiol Aging, 29, 1690, 10.1016/j.neurobiolaging.2007.04.006
Sugama, 2009, Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models, Inflamm Allergy Drug Targets, 8, 277, 10.2174/187152809789352249
Sun, 2010, Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice, Brain Res, 1335, 74, 10.1016/j.brainres.2010.03.079
Tai, 2007, Imaging microglial activation in Huntington's disease, Brain Res Bull, 72, 148, 10.1016/j.brainresbull.2006.10.029
Taylor, 2003, Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein, Hum Mol Genet, 12, 749, 10.1093/hmg/ddg074
Thiruchelvam, 2004, Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice, Eur J Neurosci, 19, 845, 10.1111/j.0953-816X.2004.03139.x
Tolosa, 2007, The premotor phase of Parkinson's disease, Parkinsonism Relat Disord, 13, S2, 10.1016/j.parkreldis.2007.06.007
Toohey, 2009, Sulfur metabolism in AIDS: cystamine as an anti-HIV agent, AIDS Res Hum Retroviruses, 25, 1057, 10.1089/aid.2009.0091
Tremblay, 2006, Neuroprotective effects of cystamine in aged parkinsonian mice, Neurobiol Aging, 27, 862, 10.1016/j.neurobiolaging.2005.04.004
Ueland, 1996, Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status–a possible element of the extracellular antioxidant defense system, J Nutr, 126, 1281S, 10.1093/jn/126.suppl_4.1281S
Van Raamsdonk, 2005, Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease, J Neurochem, 95, 210, 10.1111/j.1471-4159.2005.03357.x
Vasilescu, 1980, Interaction of sulfur-containing radioprotectors with DNA: a spectrophotometric study, Physiol Chem Phys, 12, 51
Volpicelli, 2007, Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro, J Neurochem, 102, 441, 10.1111/j.1471-4159.2007.04494.x
von Bohlen und Halbach, 2006, Regional- and age-dependent reduction in trkB receptor expression in the hippocampus is associated with altered spine morphologies, Biol Psychiatry, 59, 793, 10.1016/j.biopsych.2005.08.025
Wang, 2005, Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease, J Neurol Sci, 231, 57, 10.1016/j.jns.2004.12.011
Whitton, 2007, Inflammation as a causative factor in the aetiology of Parkinson's disease, Br J Pharmacol, 150, 963, 10.1038/sj.bjp.0707167
Yasuhara, 2005, The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model, Brain Res, 1038, 1, 10.1016/j.brainres.2004.12.055
Zhang, 2005, Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease, Faseb J, 19, 533, 10.1096/fj.04-2751com
Zheng, 1988, Radioprotection of DNA by thiols: relationship between the net charge on a thiol and its ability to protect DNA, Radiat Res, 114, 11, 10.2307/3577140
Zuccato, 2007, Role of brain-derived neurotrophic factor in Huntington's disease, Prog Neurobiol, 81, 294, 10.1016/j.pneurobio.2007.01.003
Zuccato, 2008, Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease, Brain Pathol, 18, 225, 10.1111/j.1750-3639.2007.00111.x